drugset / Trial / NCT04503629

A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.

NCT04503629

Phase 2 Completed 150 enrolled Sihuan Pharmaceutical Holdings Group Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A phase 2,double-blinded, double dummy, parallel, positive drug, randomised controlled multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD, 40mg QD compared with rabeprazole 10mg QD in patients with duodenal ulcers.

Timeline

Start
2018-10-09
Primary completion
2019-05-17
Completion
2019-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Anaprazole Other / unclassified 20 mg Oral
Subject Anaprazole Other / unclassified 40 mg Oral
Comparator Rabeprazole Small molecule 10 mg Oral

Indications